NYSE:KAPA
Kairos Pharma, LTD.
A pre-revenue biopharmaceutical firm investing heavily in R&D to develop rare disease and oncology therapies.
Key Metrics
Investment Thesis
Bull Case
Investors may view KAPA as an attractive opportunity given its substantial paid-in capital of $13.6M which provides a robust runway for advancing multiple drug candidates without immediate revenue pressure. The company's low liability structure with only $992K in current liabilities suggests prudent financial management despite being pre-revenue. Successful advancement of the pipeline could lead to blockbuster status in rare disease sectors where competition is currently limited.
Bear Case
The stock carries substantial risk due to zero revenue and a retained earnings deficit of $8.8M which indicates ongoing capital consumption without commercial returns. Negative cash flow from operations of $4.0M combined with non-cash adjustments of $1.9M suggests the business model relies entirely on external funding rather than organic growth. Investors must consider the high probability of dilution through future equity issuances to maintain solvency in a competitive pharmaceutical landscape.
About Kairos Pharma, LTD.
Kairos Pharma (KAPA) is a biopharmaceutical company focused on developing novel therapeutic solutions for rare diseases and oncology markets. The company leverages its proprietary research pipeline to deliver targeted treatments while managing minimal current liabilities against significant cash reserves. Operations are primarily concentrated in the United States with strategic potential for global expansion through licensing partnerships.
Analysis
Management Discussion
Despite a net loss of $2.6M in 2024, the company maintains a healthy working capital position with $1.3M in ending cash and minimal long-term debt obligations. The organization has successfully managed its cash flow from financing activities at $5.1M to sustain operations while investing $414K into research and development. However, the negative operating profit of $2.3M highlights the early-stage nature of the business where growth is prioritized over immediate profitability.
Industry Overview
The biopharmaceutical industry is characterized by long development cycles, high regulatory barriers, and significant upfront investment requirements before any commercial revenue is realized. Companies focusing on rare diseases often enjoy temporary market exclusivity but face challenges in achieving broad market penetration without extensive reimbursement negotiations. The sector rewards innovative science and strong clinical data while punishing capital inefficiency and late-stage trial failures.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2024 |
|---|---|
| Revenue | $0 |
| Cost of Revenue | $0 |
| Gross Profit | $0 |
| Operating Expenses | $2.3M |
| Operating Income | $-2.3M |
| R&D | $414.0K |
| G&A | $1.9M |
| Amortization | $160.0K |
| Other OpEx | $0 |
| Non-Operating Income | $0 |
| Pre-Tax Income | $-2.3M |
| Income Tax | $260.0K |
| Continuing Ops | $-2.6M |
| Discontinued Ops | $0 |
| Net Income | $-2.6M |
| Minority Interest | $0 |
| Net to Common | $-2.6M |
| Metric | 2024 |
|---|---|
| Current Assets | $4.2M |
| Prepaid Expenses | $38.0K |
| Other Current Assets | $4.1M |
| Long-Term Assets | $1.6M |
| Intangibles | $222.0K |
| Other LT Assets | $1.4M |
| Total Assets | $5.8M |
| Current Liabilities | $992.0K |
| Long-Term Liabilities | $0 |
| Total Liabilities | $992.0K |
| Shareholders' Equity | $4.8M |
| Paid-In Capital | $13.6M |
| Retained Earnings | $-8.8M |
| Total L&E | $5.8M |
| Metric | 2024 |
|---|---|
| Net Income (CFO) | $-2.6M |
| Non-Cash Adjustments | $-1.8M |
| Working Capital Changes | $434.0K |
| Cash from Operations | $-4.0M |
| Cash from Investing | $0 |
| Cash from Financing | $5.1M |
| FX Effect | $0 |
| Net Change in Cash | $1.2M |
| Beginning Cash | $93.0K |
| Ending Cash | $1.3M |
Frequently Asked Questions
How does Kairos Pharma, LTD. make money?
Rare Disease Therapeutics, Oncology Pipeline Development, Intellectual Property Licensing, Strategic Clinical Trials
What are the main risks for KAPA?
Complete lack of current revenue forcing reliance on external capital raises which could dilute shareholders, High cash burn rate from operations exceeding $4M indicating potential liquidity pressure, Significant uncertainty regarding clinical trial outcomes and regulatory approval timelines, Potential market competition from larger established pharmaceutical entities.
What is KAPA's competitive advantage?
Specialized focus on underserved rare disease markets with high unmet medical need, Proprietary patent portfolio protecting key drug candidates, Strong balance sheet providing financial flexibility for long-term R&D execution.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.